Alzheon presents positive results of ALZ-801 clinical studies
Pharmacokinetic and safety data from Phase Ib studies with ALZ-801, an optimized prodrug of tramiprosate, presented at the Alzheimer's Association International Conference.
Alzheon has announced the results from two Phase Ib studies of ALZ-801, which provide the final clinical data necessary to progress ALZ-801 into the pivotal Phase III program in Alzheimer’s disease (AD) patients who are homozygous for the ε4 allele of the apolipoprotein E gene (APOE4/4). ALZ-801 is an optimized prodrug of tramiprosate, the active agent in ALZ-801, and clinical development of ALZ-801 builds on the established safety and efficacy profile of tramiprosate from two prior Phase III trials in more than 2,000 AD patients.
The Phase Ib study results demonstrated favourable gastrointestinal tolerability, consistent and sustained plasma levels, and allowed selection of an ALZ-801 clinical dose that is bioequivalent to the tramiprosate dose that showed promising efficacy in prior Phase III trials. These data are being presented for the first time at the Alzheimer’s Association International Conference (AAIC), held 24–28 July in Toronto, Canada. Alzheon is also making a late-breaking presentation with new analyses of the prior tramiprosate Phase III studies that include: 1) pooled safety analyses from 2,025 subjects across the two studies, 2) centralized assessment of brain MRI for occurrence of vasogenic edema or amyloid-related imaging abnormalities (ARIA), and 3) efficacy analyses in the apolipoprotein E4 (APOE4) subgroups, suggesting promising efficacy and favorable safety profile in Mild and Moderate AD patients with the APOE4/4 genotype.
“We now have all of the necessary clinical, toxicology and tablet data to start the pivotal Phase 3 program with ALZ-801, an oral, amyloid-targeting drug candidate for the treatment of patients with Mild to Moderate Alzheimer’s disease,” said Martin Tolar, Founder, President and CEO of Alzheon. “Our body of ALZ-801 data and analyses suggest a well-differentiated and potentially transformative Alzheimer’s medicine: an oral tablet that targets the underlying amyloid pathology in Alzheimer’s, with compelling clinical efficacy in patients who are apolipoprotein E4 carriers. For the first approval for ALZ-801, we are preparing to initiate the ALZ-801 Phase III registration program in early 2017, focusing on the APOE4/4 homozygous patients that showed the most robust efficacy and represent a genetically-defined population with high unmet medical need.”
Alzheon conducted the two Phase Ib clinical studies of ALZ-801 in healthy elderly volunteers: a single dose tablet bioequivalence study, and a multiple-ascending dose safety, tolerability and pharmacokinetic study. These studies showed that ALZ-801 demonstrates favourable pharmacokinetic (PK) properties, including steady target plasma levels with low inter-subject variability, as well as sustained plasma concentrations up to 24 hours. ALZ-801 showed an equivalent or improved PK profile compared to tramiprosate, including plasma exposures and dose proportionality, thereby allowing bioequivalence and bridging to the prior clinical data with tramiprosate. ALZ-801 also showed a favourable safety and tolerability profile, including improved gastrointestinal tolerability with lower incidence of nausea and vomiting compared to previous studies with tramiprosate.
“We are extremely pleased with these clinical results for ALZ‐801, which show that we have successfully optimized the pharmaceutical, pharmacokinetic and tolerability profile so that ALZ-801 is well positioned to advance into Phase III pivotal studies, and to potentially offer an important advance in AD treatment. In addition, we are excited to show that we have developed a simple, yet superior immediate-release tablet dose that can be used in the Phase III program and subsequently in broad commercial development,” said John Hey, Chief Scientific Officer of Alzheon.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance